Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer

Pancreatic cancer remains a clinical challenge, thus new therapies are urgently needed. The selective Wee1 inhibitor MK-1775 has demonstrated promising results when combined with DNA damaging agents, and more recently with CHK1 inhibitors in various malignancies. We have previously demonstrated that...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Lett
Asıl Yazarlar: Wang, Guan, Niu, Xiaojia, Zhang, Wenbo, Caldwell, J. Timothy, Edwards, Holly, Chen, Wei, Taub, Jeffrey W., Zhao, Lijing, Ge, Yubin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282784/
https://ncbi.nlm.nih.gov/pubmed/25458954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2014.10.015
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller